Two-Year Safety and Efficacy Outcomes with Fostamatinib in Adult Patients with Immune Thrombocytopenia (ITP): Open-Label Extension to Phase 3 Trial Program

被引：8
|
作者：
Duliege, Anne-Marie [1 ]
Arnold, Donald M. [2 ]
Boccia, Ralph [3 ]
Boxer, Michael [4 ]
Cooper, Nichola [5 ]
Hill, Quentin A. [6 ]
Liles, Darla K. [7 ]
Sholzberg, Michelle [8 ]
Zayed, Hany [1 ]
Tong, Sandra [1 ]
Bussel, James B. [9 ]
机构：
[1] Rigel Pharmaceut Inc, San Francisco, CA USA
[2] McMaster Univ, Dept Med, Michael G DeGroote Sch Med, Hamilton, ON, Canada
[3] Ctr Canc & Blood Disorders, Bethesda, MD USA
[4] Arizona Oncol, Tucson, AZ USA
[5] Imperial Coll NHS Trust, London, England
[6] St James Univ Hosp, Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England
[7] East Carolina Univ, Vidant Med Ctr, Div Hematol Oncol, Greenville, NC 27858 USA
[8] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada
[9] New York Presbyterian Hosp, Weill Cornell Med Ctr, Dept Pediat, Div Pediat Hematol Oncol, New York, NY USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-110482
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
736
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Efficacy and Safety of Switching from Adalimumab to Sarilumab in an Open-Label Extension of a Phase 3 Monotherapy Trial in Patients with Active Rheumatoid Arthritis
    Burmester, Gerd R.
    Fiore, Stefano
    Hu, Chih-Chi
    Fay, Jonathan
    Lee, Eun Bong
    Genovese, Mark C.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [32] Telotristat Ethyl in Carcinoid Syndrome: Safety and Efficacy Results of an Open-Label Extension of the TELECAST Phase 3 Clinical Trial
    Pavel, Marianne
    Benavent, Marta
    Perros, Petros
    Srirajaskanthan, Raj
    Warner, Richard R. P.
    Kulke, Matthew H.
    Anthony, Lowell B.
    Kunz, Pamela L.
    Hoersch, Dieter
    Lapuerta, Pablo
    Fleming, Rosanna
    Gross, David J.
    PANCREAS, 2018, 47 (03) : 350 - 350
  • [33] Telotristat Ethyl in Carcinoid Syndrome: Safety and Efficacy Results of an Open-Label Extension of the TELECAST Phase 3 Clinical Trial
    Pavel, M.
    Benavent, M.
    Perros, P.
    Srirajaskanthan, R.
    Warner, R. R. P.
    Kulke, M. H.
    Anthony, L. B.
    Kunz, P.
    Hoersch, D.
    Lapuerta, P.
    Fleming, R.
    Gross, D.
    NEUROENDOCRINOLOGY, 2017, 105 : 205 - 205
  • [34] Long-term oral lacosamide in painful diabetic neuropathy: A two-year open-label extension trial
    Shaibani, Aziz
    Biton, Victor
    Rauck, Richard
    Koch, Brigitte
    Simpson, Jeffrey
    EUROPEAN JOURNAL OF PAIN, 2009, 13 (05) : 458 - 463
  • [35] FINAL SAFETY AND EFFICACY DATA OF LONG-TERM OPEN-LABEL DOSING OF SUBCUTANEOUS (SC) ROMIPLOSTIM IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA (ITP)
    Tarantino, Michael
    Bussel, James
    Blanchette, Victor
    Beam, Donald
    Roy, John
    Despotovic, Jenny
    Raj, Ashok
    Carpenter, Nancy
    Mehta, Bhaki
    Eisen, Melissa
    PEDIATRIC BLOOD & CANCER, 2018, 65
  • [36] A Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous Romiplostim in Children with Immune Thrombocytopenia (ITP)
    Grainger, John
    Bussel, James
    Cooper, Nichola
    Tarantino, Michael
    Blanchette, Victor
    Despotovic, Jenny
    Maschan, Alexey
    Carpenter, Nancy
    Eisen, Melissa
    Mehta, Bhakti
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S10 - S10
  • [37] Garadacimab for hereditary angioedema prophylaxis: Efficacy and safety from a Phase 2 open-label extension trial
    Craig, T. J.
    Reshef, A.
    Lumry, W. R.
    Saguer, I. Martinez
    Jacobs, J. S.
    Yang, W. H.
    Aygoren-Pursun, E.
    Keith, P. K.
    Busse, P.
    Magerl, M.
    Feuersenger, H.
    Bica, M. A.
    Glassman, F.
    Pragst, I.
    Levy, D. S.
    ALLERGOLOGIE, 2023, 46 (08) : 560 - 561
  • [38] Final Safety and Efficacy Data of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)
    Tarantino, Michael
    Bussel, James B.
    Blanchette, Victor S.
    Beam, Donald
    Roy, John
    Despotovic, Jenny M.
    Raj, Ashok
    Carpenter, Nancy
    Mehta, Bhakti
    Eisen, Melissa
    BLOOD, 2017, 130
  • [39] Efficacy and safety of cannabidiol for seizures associated with tuberous sclerosis complex in paediatric and adult patients from GWPCARE6: A phase 3 trial with open-label extension
    Saurer, T. B.
    Thiele, E. A.
    Lawson, J. A.
    Kotulska, K.
    Sahebkar, F.
    Greco, T.
    EPILEPSIA, 2024, 65 : 180 - 181
  • [40] Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment: Interim Results From the LUCENT-3 Open-Label Extension Study
    Sands, Bruce E.
    D'Haens, Geert
    Clemow, David B.
    Irving, Peter M.
    Johns, Jordan
    Gibble, Theresa Hunter
    Abreu, Maria T.
    Lee, Scott
    Hisamatsu, Tadakazu
    Kobayashi, Taku
    Dubinsky, Marla C.
    Vermeire, Severine
    Siegel, Corey A.
    Peyrin-Biroulet, Laurent
    Moses, Richard E.
    Milata, Joe
    Arora, Vipin
    Panaccione, Remo
    Dignass, Axel
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S627 - S627
12345